RT Journal Article
SR Electronic
T1 Automating Clinical Phenotyping Using Natural Language Processing: An Application for Crohn’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.16.23297099
DO 10.1101/2023.10.16.23297099
A1 Schmidt, Linea
A1 Ibing, Susanne
A1 Borchert, Florian
A1 Hugo, Julian
A1 Marshall, Allison A.
A1 Peraza, Jellyana
A1 Cho, Judy H.
A1 Böttinger, Erwin P.
A1 Renard, Bernhard Y.
A1 Ungaro, Ryan C.
YR 2024
UL http://medrxiv.org/content/early/2024/09/12/2023.10.16.23297099.abstract
AB Real-world studies based on electronic health records often require manual chart review to derive patients’ clinical phenotypes, a labor-intensive task with limited scalability. Here, we developed and compared computable phenotyping based on rules using the spaCy frame-work and a Large Language Model (LLM), GPT-4, for disease behavior and age at diagnosis of Crohn’s disease patients. We are the first to describe computable phenotyping algorithms using clinical texts for these complex tasks with previously described inter-annotator agreements between 0.54 and 0.98. The data comprised clinical notes and radiology reports from 584 Mount Sinai Health System patients. Overall, we observed similar or better performance using GPT-4 compared to the rules. On a note-level, the F1 score was at least 0.90 for disease behavior and 0.82 for age at diagnosis. We could not find statistical evidence for a difference to the performance of human experts on this task. Our findings underline the potential of LLMs for computable phenotyping.Competing Interest StatementRCU has served as a consultant and/or advisory board member for AbbVie, Bristol Myers Squibb, Celltrion, Inotrem, Lilly, Janssen, Pfizer, Roivant, Takeda. BYR has served as a consultant and/or holds intellectual property rights commercialized by Seqstant, Biontech, Genentech (Roche). The remaining authors declare no conflict of interest.Funding StatementThis work is supported in part through the use of the research platform AI-Ready Mount Sinai (AIR.MS), and through the MSDW resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai. This work was funded by the Joachim-Herz Foundation (to SI), and the Hasso Plattner Foundation (HPF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Program of Protection for Human Subjects at the Icahn School of Medicine at Mount Sinai.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are not publicly available as it contains protected health information.